Allos Therapeutics Requests Re-Examination of CHMP Opinion on FOLOTYN® in PTCL at the European Medicines Agency

Allos Therapeutics, Inc. (NASDAQ: ALTH) today announced that it has submitted a request to the European Medicines ...

Press Release

Allos Therapeutics Inc. Posted on:30 Jan 12 Allos Therapeutics, Inc. (NASDAQ: ALTH) today announced that it has submitted a request to the European Medicines Agency (EMA) for a re-examination of the negative opinion issued in January by the EMA’s Committee For Medicinal Products for Human Use (CHMP) for conditional approval of FOLOTYN® (pralatrexate injection) for the treatment of patients with ...

A quiz for Joe Oliver: How many died building CPR?

Comparison of railway to pipeline ridiculous